Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N3 |
Molecular Weight | 265.3529 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CN(C)CCN1C3=C(CC4=C2C=CC=C4)C=CC=N3
InChI
InChIKey=RONZAEMNMFQXRA-MRXNPFEDSA-N
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1
Molecular Formula | C17H19N3 |
Molecular Weight | 265.3529 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Esmirtazapine (S-(+)mirtazapine or ORG-50081) is an enantiomer of mirtazapine (REMERON®), a high-affinity antagonist at 5-HT2/5-HT3 and H1 receptors, used in the treatment of depression. Esmirtazapine has a shorter plasma half-life than the R(−) enantiomer. Esmirtazapine is preferentially metabolized into an 8-hydroxy glucuronide. Organon was developing esmirtazapine for the treatment of hot flushes (vasomotor symptoms) associated with the menopause and insomnia.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Behavioral disturbances in dementia. | 2003 Mar |
|
Compliance: the impact of adverse events and tolerability on the physician's treatment decisions. | 2003 Sep |
|
Hypertensive urgency with clonidine and mirtazepine. | 2004 Sep-Oct |
|
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. | 2005 |
|
Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. | 2005 Dec |
|
Antidepressants and seizures: emphasis on newer agents and clinical implications. | 2005 Dec |
|
Evidence of cost-effective treatments for depression: a systematic review. | 2005 Jan |
|
Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. | 2005 Mar |
|
Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. | 2005 May |
|
Mirtazepine for MDMA-induced depression. | 2005 May-Jun |
|
Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. | 2005 Nov-Dec |
|
Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzotriazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4,14b-tetrahydro-2H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzothiadiazepine 10,10-dioxide (tiaaptazepine). | 2005 Nov-Dec |
|
[Distribution effects of orthographic similarity and priming by masked repetition]. | 2005 Sep |
|
[Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet]. | 2006 |
|
Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. | 2006 Dec |
|
Prophylaxis of migraine. | 2006 Sep |
|
Family history, early adversity and the hypothalamic-pituitary-adrenal (HPA) axis: Mediation of the vulnerability to mood disorders. | 2007 |
|
[Differentiated approach to the therapy of endogenous anxious depression]. | 2007 |
|
[Depressive disturbances during antiviral therapy in patients with type C hepatitis]. | 2007 |
|
Post-traumatic stress disorder. | 2007 Aug 1 |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
Essential tremor. | 2007 May 1 |
|
Toward achieving optimal response: understanding and managing antidepressant side effects. | 2008 |
|
5-HT(2A) inverse-agonists for the treatment of insomnia. | 2008 |
|
Triple reuptake inhibitors: the next generation of antidepressants. | 2008 Dec |
|
Pharmacological management of panic disorder. | 2008 Feb |
|
Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. | 2008 Jan |
|
A postmenopausal woman presenting with Ekbom syndrome associated with recurrent depressive disorder: a case report. | 2008 Jul 22 |
|
Routing protocols in wireless sensor networks. | 2009 |
|
Brain-derived neurotrophic factor: role in depression and suicide. | 2009 |
|
Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
Mirtazapine: a review of its use in major depression and other psychiatric disorders. | 2009 |
|
Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. | 2009 Apr |
|
Brain potentials of conflict and error-likelihood following errorful and errorless learning in obsessive-compulsive disorder. | 2009 Aug 12 |
|
Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. | 2009 Aug 7 |
|
Ethyl carbamate in alcoholic beverages from Mexico (tequila, mezcal, bacanora, sotol) and Guatemala (cuxa): market survey and risk assessment. | 2009 Jan |
|
Sexual side-effects of contemporary antidepressants: review. | 2009 Sep |
|
Extreme thermal sensitivity and pain-induced sensitization in a fibromyalgia patient. | 2010 |
|
Local smoke-free policy development in Santa Fe, Argentina. | 2010 Apr |
|
Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. | 2010 Dec 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:07:07 GMT 2023
by
admin
on
Sat Dec 16 17:07:07 GMT 2023
|
Record UNII |
4685R51V7M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1366933
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
61337-87-9
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
262-714-0
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
DB06678
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
8620
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
DTXSID001029320
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
3085218
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
4685R51V7M
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
100000174926
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
C76963
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY | |||
|
ESMIRTAZAPINE
Created by
admin on Sat Dec 16 17:07:08 GMT 2023 , Edited by admin on Sat Dec 16 17:07:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN-VIVO
Scientific Literature
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|